Switch to:
More From Other Websites
Tesaro won’t reveal price of ovarian cancer drug. But it’ll likely be near $14,000 a month Mar 28 2017
Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer Mar 28 2017
Amazon, Red Hat, Tesaro Price Targets Raised; Snap Started At Hold Mar 28 2017
Amazon buys Middle East online retailer, Tencent takes stake in Tesla, American Airlines buys China... Mar 28 2017
BUZZ-AstraZeneca cancer drug faces new competition from Tesaro Mar 28 2017
Tesaro Secures FDA Nod for Ovarian Cancer Drug Mar 28 2017
Tesaro wins FDA approval for potential blockbuster cancer drug Mar 27 2017
Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Mar 27 2017
Tesaro stock rises 6% on news that its ovarian cancer drug was approved by the FDA Mar 27 2017
Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer Mar 27 2017
TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer Mar 27 2017
3:47 pm Tesaro provides update, confirms FDA approval of ZEJULA, says implementing plans to initiate... Mar 27 2017
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line... Mar 27 2017
AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis... Mar 16 2017
Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst Mar 15 2017
Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology... Mar 15 2017
AstraZeneca Ovarian Cancer Drug Succeeds in Trial Mar 15 2017
Lynparza Vs. Niraparib Mar 15 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK